SRF delivered results which were only marginally below our estimates. While Revenue grew by 6% YoY, EBITDA and Adjusted PAT grew by impressive rates of 26% and 86%. The chemicals business continued to exhibit strong growth owing to higher HFC pricing and placement of higher volumes in domestic and export markets. Although some orders have been deferred on the agro side, the management expects to recoup majority of the same in Q4FY26. Pent up purchase orders are expected to convert in Q4FY26 leading to a robust quarter, a trend which was seen in Q4FY25 as well. Specialty Chemicals Business grew on...